Outlook Therapeutics Inc represents values of innovation, dedication, and patient-centricity. The company is committed to developing and commercializing ophthalmic products for improved vision and outcomes. With a focus on developing monoclonal antibodies, Outlook Therapeutics aims to address unmet needs in the ocular disease market. The company's corporate philosophy centers around scientific excellence, collaboration with healthcare professionals, and delivering value to patients. By leveraging cutting-edge technology and strategic partnerships, Outlook Therapeutics strives to enhance the quality of life for individuals affected by various eye conditions.

Outlook Therapeutics Inc is primarily present in the United States.

Outlook Therapeutics Inc has achieved significant milestones in its journey. One of the major milestones includes the successful completion of a Phase 3 clinical trial for its lead product, ONS-5010, a potential treatment for wet age-related macular degeneration (wet AMD). Additionally, the company has obtained FDA Fast Track Designation and Breakthrough Therapy Designation for ONS-5010, acknowledging its potential to address an unmet need in the market. Outlook Therapeutics Inc has also partnered with BioLexis Pte. Ltd. for the commercialization of ONS-5010 in Greater China. These achievements highlight the company's commitment to developing innovative therapies and its potential for growth in the biopharmaceutical industry.

Outlook Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative ophthalmic products. With a history spanning several years, Outlook Therapeutics Inc has made significant advancements in the field of ophthalmology. The company's mission is to address unmet needs in ophthalmic treatments and improve the lives of patients worldwide. Through rigorous research and development efforts, Outlook Therapeutics Inc has developed promising therapies that aim to revolutionize the treatment of various ocular diseases. With a dedicated team of experts and an unwavering commitment to innovation, Outlook Therapeutics Inc continues to make strides in the field of ophthalmology.

The main competitors of Outlook Therapeutics Inc in the market include other pharmaceutical companies specializing in ophthalmology and developing treatments for retinal diseases. Some prominent competitors include Roche Holding AG, Novartis International AG, Regeneron Pharmaceuticals Inc, and Allergan plc. These companies offer a range of therapies and treatments for various eye conditions, creating a competitive market for Outlook Therapeutics Inc.

Outlook Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Outlook Therapeutics Inc. is focused on developing and commercializing innovative biopharmaceutical products for the treatment of ocular diseases. The company uses its proprietary ONS-5010 ophthalmic formulation of bevacizumab, a well-known anti-vascular endothelial growth factor (anti-VEGF) antibody, to target various retinal diseases. By leveraging this therapeutic platform, Outlook Therapeutics aims to address unmet medical needs in ophthalmology and provide cost-effective solutions for patients and healthcare providers. Through research, development, and strategic partnerships, the company aims to improve the vision and quality of life for individuals suffering from ocular diseases.

Outlook Therapeutics의 P/E 비율은 -0.39입니다.

Outlook Therapeutics의 P/S 비율은 0입니다.

Outlook Therapeutics에 대한 AlleAktien 품질 점수는 4/10입니다.

Outlook Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

예상되는 Outlook Therapeutics 이익은 -226.44 백만 USD입니다.

Outlook Therapeutics Inc. is a publicly traded biotechnology company specializing in the development and marketing of pharmaceuticals for ophthalmology. The company was founded in 2018 and is headquartered in Cranbury, New Jersey. The business model of Outlook Therapeutics is to develop and market innovative and effective drugs for eye diseases. The company is divided into two business segments: one for drug development and the other for marketing these drugs. In terms of drug development, Outlook Therapeutics has the potential to revolutionize the ophthalmology industry. The company focuses on developing innovative biosimilars, which are biopharmaceuticals manufactured similarly to already approved biological drugs, ensuring they are equally effective and safe as the original products. With this strategy, Outlook Therapeutics can bring drugs to market faster and at lower costs. One specific product that Outlook Therapeutics is working on is ONS-5010 Beovu Biosimilar. It is a replica of Novartis' drug Beovu®, used to treat eye diseases such as wet age-related macular degeneration (AMD). Beovu is used by many patients worldwide, but since its patent protection expires in the US, Outlook Therapeutics can bring its biosimilar ONS-5010 to market. The other business segment of Outlook Therapeutics is drug marketing. Once Outlook Therapeutics develops a biosimilar, it is licensed and marketed by other companies. Outlook Therapeutics focuses on selling licenses that allow other companies to use its products. This way, the company can increase its revenue without having to build a large distribution network. Outlook Therapeutics has also formed a special partnership with Alvogen, an international pharmaceutical company. Alvogen will be the exclusive distribution partner for ONS-5010 Beovu Biosimilar in the CIS countries, including Russia, Ukraine, Kazakhstan, Belarus, and Kyrgyzstan. Overall, Outlook Therapeutics is working on innovative solutions to combat eye diseases, focusing on the development of biosimilars. With this strategy, the company is able to achieve faster drug approvals while prioritizing patient treatment. Through its partnerships and licenses, the company can bring its products to market quickly and effectively, thus strengthening its influence in ophthalmology.

Outlook Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Outlook Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Outlook Therapeutics의 ISIN은 US69012T2069입니다.

Outlook Therapeutics의 WKN은 A2PF3C입니다.

Outlook Therapeutics의 티커는 OTLK입니다.

지난 12개월 동안 Outlook Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Outlook Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Outlook Therapeutics의 현재 배당 수익률은 입니다.

Outlook Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Outlook Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Outlook Therapeutics은 '건강' 섹터에 속합니다.

Outlook Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Outlook Therapeutics는 0 USD를 배당금으로 지급했습니다.

Outlook Therapeutics의 배당금은 USD에 지급됩니다.